EuroPCR 2024 | OBSERVANT II: TAVR in the “Real World”

This study analyzed 2,493 “real world” patients, 1,352 receiving the Evolut R/Pro, 675 the SAPIEN, 3,270 the Acurate Neo and 192 the Portico.

Primary end point was all cause mortality and major adverse cardiovascular events (MACE) at 5 years.  

Populations were similar, with EuroSCORE 4.9%, and there were no significant differences in comorbidities or echocardiographic parameters. 

At 5 years, there were no differences in primary end point, neither were there any differences in all-cause mortality, stroke, MI or need for valve reintervention. 

It was also observed that patients receiving the SAPIEN 3 saw fewer hospitalizations for cardiac failure vs. the rest of patients. 

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Long-term multiple comparison of transcatheter aortic valves – insights from the OBSERVANT II study.

Reference: Giuliano Costa.

• Facebook
• Twitter
• Instagram
• LinkedIn
• YouTube